NEO NEOGENOMICS INC
Services-Testing Laboratories · Nasdaq · SEC CIK 1077183 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY11.1%
TTM net income YoY71.5%
TTM EPS YoY71.6%
Revenue 3-yr CAGR11.1%
Net income 3-yr CAGR—
Margins
Gross margin44.8%
Operating margin-6.3%
Net margin-4.1%
FCF margin-3.6%
EBITDA margin-1.9%
Returns
ROE-3.9%
ROA-2.3%
ROIC (approx.)-4.6%
Asset turnover0.57x
Leverage & solvency
Liabilities / assets41.9%
Debt / equity0.47x
Current ratio3.53x
Interest coverage-15.21x
Cash quality & payout
Operating cash flow / net income-0.13x
Accruals ratio-2.7%
Payout ratio—
Capex / revenue4.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $209.25M | $201.66M | $186.67M | $190.17M | $187.80M | $181.33M | $168.03M | $172.00M |
| Cost of revenue | $112.67M | $109.78M | $105.81M | $106.83M | $107.35M | $104.07M | $94.79M | $94.74M |
| Gross profit | $96.59M | $91.88M | $80.86M | $83.34M | $80.45M | $77.26M | $73.25M | $77.26M |
| R&D expense | $9.86M | $10.76M | $9.53M | $9.18M | $8.69M | $9.02M | $10.18M | $7.97M |
| SG&A expense | $67.07M | $63.61M | $65.74M | $63.51M | $69.87M | $71.75M | $68.21M | $63.64M |
| Operating income | -$7.94M | -$9.77M | -$18.24M | -$13.41M | -$27.01M | -$47.63M | -$27.82M | -$18.40M |
| Interest expense | $1.27M | $781,000 | $598,000 | $599,000 | $603,000 | $933,000 | $1.62M | $1.62M |
| Pretax income | -$8.02M | $1.83M | -$17.58M | -$12.41M | -$26.39M | -$45.82M | -$25.66M | -$16.13M |
| Income tax | -$475,000 | -$412,000 | -$472,000 | -$2.52M | $740,000 | -$724,000 | $266,000 | -$804,000 |
| Net income | -$7.55M | $2.24M | -$17.11M | -$9.88M | -$27.13M | -$45.09M | -$25.92M | -$15.32M |
| EBITDA | $615,000 | -$1.20M | -$9.46M | -$4.65M | -$18.21M | -$38.49M | -$18.46M | -$8.57M |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Weighted avg. shares (diluted) | 128.59M | 130.83M | 129.17M | — | 128.41M | 127.95M | 127.38M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $139.28M | $145.54M | $146.14M | $159.62M | $164.12M | $154.72M | $346.19M | $367.01M |
| Receivables | $213.41M | $175.41M | $167.42M | $159.24M | $155.30M | $153.12M | $151.21M | $150.54M |
| Inventory | $25.50M | $27.14M | $29.84M | $28.57M | $28.46M | $34.17M | $29.77M | $26.75M |
| Current assets | $410.08M | $381.48M | $373.68M | $376.29M | $382.46M | $392.55M | $573.93M | $596.02M |
| PP&E, net | $85.94M | $80.94M | $83.66M | $84.83M | $85.47M | $85.46M | $89.60M | $94.10M |
| Goodwill | $524.00M | $524.00M | $524.00M | $524.34M | $524.34M | $524.14M | $522.77M | $522.77M |
| Intangibles | $263.63M | $271.26M | $278.89M | $286.53M | $294.16M | $301.80M | $331.32M | $339.68M |
| Total assets | $1.38B | $1.35B | $1.35B | $1.36B | $1.37B | $1.39B | $1.60B | $1.64B |
| Current liabilities | $116.17M | $105.88M | $84.59M | $88.30M | $97.87M | $100.12M | $279.69M | $301.24M |
| Short-term debt | — | — | — | $0 | — | — | — | $200.78M |
| Long-term debt | $374.69M | $374.24M | — | $341.86M | — | — | — | $340.33M |
| Total debt | $374.69M | $374.24M | — | $341.86M | — | — | — | $541.11M |
| Total liabilities | $576.28M | $566.51M | $517.77M | $523.27M | $536.49M | $539.91M | $713.16M | $735.70M |
| Shareholders' equity | $800.64M | $785.73M | $828.76M | $836.56M | $838.29M | $854.04M | $888.27M | $902.34M |
| Net debt | $235.41M | $228.70M | — | $182.24M | — | — | — | $174.10M |
| Shares outstanding | 129.10M | 127.92M | 129.65M | 128.99M | 128.89M | 128.68M | 128.36M | 128.15M |
| Cash flow statement | ||||||||
| Operating cash flow | -$8.88M | $19.96M | -$8.14M | $1.34M | $8.88M | $20.33M | -$25.33M | $9.80M |
| Capital expenditure | $11.77M | $8.22M | $5.00M | $7.87M | $8.31M | $6.32M | $4.50M | $11.60M |
| Free cash flow | -$20.66M | $11.74M | -$13.14M | -$6.53M | $570,000 | $14.01M | -$29.83M | -$1.80M |
| Investing cash flow | -$11.85M | -$8.32M | -$5.00M | -$6.30M | -$277,000 | -$9.31M | $3.56M | -$5.47M |
| Financing cash flow | $14.47M | -$12.24M | -$338,000 | $431,000 | $765,000 | -$202.43M | $949,000 | $687,000 |
| Depreciation & amortization | $8.56M | $8.58M | $8.78M | $8.76M | $8.80M | $9.14M | $9.37M | $9.83M |
| Stock-based compensation | $8.84M | $8.22M | $9.64M | $8.04M | $10.30M | $12.21M | $10.75M | $8.33M |
| Share buybacks | $0 | — | — | — | $0 | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.